Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against ...

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), currently trading at $0.58 with a market capitalization of $33.37 million, disclosed the results of its annual meeting of stockholders held on May ...

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), currently trading at $0.58 with a market capitalization of $33.37 million, disclosed the results of its annual meeting of stockholders held on May 28, ...

SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...

In a recent 8-K filing with the Securities and Exchange Commission, Rani Therapeutics Holdings , Inc., a Delaware-incorporated pharmaceutical company, announced entering into a significant ...

May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

Rani Therapeutics announced positive preclinical data for RT-114 and semaglutide, advancing toward Phase 1 obesity trials in mid-2025. Rani Therapeutics Holdings, Inc. has announced preclinical ...

Rani Therapeutics Holdings, Inc. has announced a research agreement with Chugai Pharmaceutical Co., Ltd. to evaluate the potential of Rani’s oral delivery technology, specifically the RaniPill ...

RANI READ THE FULL RANI RESEARCH REPORT On May 13 th Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported first quarter 2025 results. Year to date, Rani has updated investors on ProGen’s PG102 ...

SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs ...

SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...